Biotech Analysis Central Pharma News: Celgene's Protocol Change, Roche's BLA For Herceptin, Amgen's Resubmission For Osteoporosis [Seeking Alpha]
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Seeking Alpha
Summary Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Celgene Amends Protocol For Phase 2 Multiple Myeloma Study News: Recently, Celgene ( CELG ) announced that it had amended the protocol for a phase 2 study known as KarMMa. This study is assessing a CAR-T product known as bb2121 to treat patients with relapsed/refractory multiple myeloma (MM). Celgene is developing this product with its partner Bluebird Bio ( BLUE ). The reason for amending the protocol of this phase 2 study was so that it could increase the dosage of CAR-T cells from 15 - 30 x 10 7 cells to 15 - 45 x 10 7. Along with changing the protocol for that study, it has also amended the protocol for the phase 1 study known s CRB-401 , which is treating adults with multiple myeloma who express the BCMA gene. It increased enrollment for this study by 20 patients and also increased the dose as well to m
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit – BLUEAccesswire
- DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmAccesswire
- Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc.(BLUE) ShareholdersAccesswire
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BLUEAccesswire
- Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BLUEAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 4/16/24 - Form 8-K
- 4/10/24 - Form SC
- 3/26/24 - Form 8-K
- BLUE's page on the SEC website